

1. An antibody variable region comprising the amino acid sequence set forth in SEQ ID NO: 1.
2. An antibody variable region comprising the amino acid sequence set forth in SEQ ID NO: 2.
3. The antibody variable region of claim 2 further comprising the amino acid sequence set forth in SEQ ID NO: 1.
4. The antibody variable region of claim 3, wherein the amino acid sequences are linked by a disulfide bond.
5. The antibody variable region of claim 3, wherein the amino acid sequences are linked by a peptide bond.
6. An antibody variable region comprising an amino acid sequence selected from the group consisting of amino acids 1-23 of SEQ ID NO: 1, amino acids 1-25 of SEQ ID NO: 2, and amino acids 67-98 of SEQ ID NO: 2, wherein the antibody variable region specifically binds to GD2.
7. The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 1-23 of SEQ ID NO: 1.
8. The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 1-25 of SEQ ID NO: 2.
9. The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 67-98 of SEQ ID NO: 2.
10. A polypeptide comprising the antibody variable region of claim 6 and an Fc portion comprising at least a CH2 domain.
11. The polypeptide of claim 10, wherein the Fc portion is derived from IgG1.
12. A nucleic acid encoding the antibody variable region of claim 6.

13. A cell comprising the nucleic acid of claim 12.
14. A method for targeting a cell with GD2 on its surface, the method comprising:
administering the antibody variable region of claim 6.
15. The method of claim 14, wherein the cell is a tumor cell.
16. A fusion protein comprising the antibody variable region of claim 6 and a non-immunoglobulin moiety.
17. The fusion protein of claim 16, wherein the non-immunoglobulin moiety is a cytokine.
18. The fusion protein of claim 17, wherein the cytokine is selected from the group consisting of an interleukin, a hematopoietic factor, a lymphokine, an interferon, and a chemokine.
19. The fusion protein of claim 18, wherein the interleukin is selected from the group consisting of interleukin-2 (IL-2) and interleukin-12 (IL-12).
20. The fusion protein of claim 18, wherein the hematopoietic factor is granulocyte-macrophage colony stimulating factor (GM-CSF).
21. The fusion protein of claim 18, wherein the lymphokine is a lymphotoxin.
22. The fusion protein of claim 18, wherein the interferon is selected from the group consisting of interferon- α , interferon- β , and interferon- γ .
23. The fusion protein of claim 16 further comprising a second non-immunoglobulin moiety.
24. The fusion protein of claim 23, wherein the fusion protein comprises IL-2 and IL-12.

25. A method for treating a patient, the method comprising:
administering to a patient the nucleic acid of claim 12.
26. A method for treating a patient, the method comprising:
administering to a patient the cell of claim 13.